A5102980873- Asthma and respiratory diseases
- Eosinophilic Esophagitis
- IL-33, ST2, and ILC Pathways
- Allergic Rhinitis and Sensitization
- Respiratory and Cough-Related Research
- Sinusitis and nasal conditions
- Eosinophilic Disorders and Syndromes
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory Support and Mechanisms
- Pediatric health and respiratory diseases
- Nasal Surgery and Airway Studies
- Hemoglobinopathies and Related Disorders
- Urticaria and Related Conditions
- Esophageal and GI Pathology
- Dermatology and Skin Diseases
- Head and Neck Surgical Oncology
- Delphi Technique in Research
- Iron Metabolism and Disorders
- Inhalation and Respiratory Drug Delivery
- Neonatal Respiratory Health Research
- Pharmacological Effects and Toxicity Studies
- Prenatal Screening and Diagnostics
- Hematological disorders and diagnostics
- Bone health and treatments
- Erythropoietin and Anemia Treatment
Regeneron (United States)
2021-2025
Sanofi (France)
2022-2024
GW Pharmaceuticals (United Kingdom)
2023-2024
Harvard University
2024
Temple University
2024
American Academy of Otolaryngology — Head and Neck Surgery
2024
Novartis (Switzerland)
2022
Novartis (China)
2022
Boehringer Ingelheim (Egypt)
2022
Ghent University Hospital
2022
Transient increases in blood eosinophil counts have been observed dupilumab clinical trials.To assess and eosinophilia-related treatment-emergent adverse events (TEAEs) across 11 trials, comparing adult adolescent patients with asthma chronic rhinosinusitis nasal polyps (CRSwNP), atopic dermatitis, eosinophilic esophagitis.Eosinophil counts, rates of TEAEs or eosinophilia (>1,500 cells/μL), discontinuations, symptoms, efficacy CRSwNP are presented.Transient mean were dupilumab-treated (mean...
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease treated sinus surgery when refractory to medical intervention. However, recurrence postsurgery common. Dupilumab, fully human monoclonal antibody, blocks the shared receptor for interleukin 4 (IL‐4) and IL‐13, key central drivers of inflammation. We report efficacy dupilumab in patients CRSwNP from SINUS‐24/SINUS‐52 trials (NCT02912468/NCT02898454), by number prior surgeries time since last surgery....
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition of the lungs, characterized by chronic respiratory symptoms, primarily dyspnea, cough, and sputum production, due to airway and/or alveoli abnormalities that cause persistent, often progressive, airflow obstruction. Although underlying mechanisms responsible for COPD remain poorly understood, over last several decades, clinical phenotypes endotypes have been suggested. These include frequent exacerbator eosinophilic...
The global Assessing long-teRm Outcomes in dupiluMAb (AROMA) registry study aims to characterize the long-term, real-world use of dupilumab patients with chronic rhinosinusitis nasal polyps (CRSwNP). This paper reports interim analysis baseline characteristics for first 303 enrolled AROMA. AROMA is currently ongoing adult CRSwNP who initiated up 36 months. describes demographics; systemic/oral corticosteroid (SCS/OCS) and antibiotic use; disease burden; healthcare resource utilization;...
This post hoc analysis of the international SINUS-24/-52 trials (NCT02912468/NCT02898454) aimed to assess dupilumab efficacy in patients with severe chronic rhinosinusitis nasal polyps (CRSwNP) according different definitions type 2 inflammatory signature.
Purpose: Dupilumab significantly reduced the requirement for systemic corticosteroids (SCS) in patients with severe chronic rhinosinusitis nasal polyps (CRSwNP). Patients CRSwNP and coexisting asthma typically have a higher disease burden more difficulty managing disease. Here, we report an analysis of outcomes SCS use asthma. Methods: This was post hoc randomized, placebo-controlled SINUS-24 SINUS-52 studies (NCT02912468/NCT02898454) (patient self-reported) from pooled intention-to-treat...
In phase 3 VOYAGE (NCT02948959; Evaluation of Dupilumab in Children With Uncontrolled Asthma), dupilumab showed clinical efficacy with an acceptable safety profile children aged 6 to 11 years uncontrolled moderate severe type 2 asthma (blood eosinophils ≥150 cells/μL or FeNO ≥20 ppb). We analyzed dupilumab's by high- medium-dose inhaled corticosteroids (ICS) at baseline. were randomized receive add-on 100/200 mg (by body weight ≤30 kg/>30 kg) every weeks placebo for 52 and stratified ICS End...
SUMMARY Background The problem of iron‐overload observed in thalassemia patients can be overcome using chelating agents such as deferiprone (Ferroprox ® ), deferasirox (Exjade ) and deferoxamine (Desferal ). Although these drugs used monotherapy, combined therapy, especially with deferoxamine, has led to promising outcomes various studies. Methods Materials In this quasi‐experimental study, serum ferritin levels were evaluated 32 β‐thalassemia major severe iron overload before after...
Abstract Objectives To assess the severity of top 5 22‐item Sino‐Nasal Outcome Test (SNOT‐22) items ranked most important by patients with chronic rhinosinusitis nasal polyps (CRSwNP), effect dupilumab on these items, and their association objective disease measures. Study Design Post hoc analysis SINUS‐24 (NCT02912468) SINUS‐52 (NCT02898454) clinical trials. Setting Multinational, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group studies. Methods Patients SNOT‐22...
Changes from baseline in fractional exhaled nitric oxide (FeNO) and blood eosinophil count (Eos) may be related to efficacy outcomes dupilumab-treated patients with moderate-to-severe asthma.
Background Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly is approved the treatment of EoE in patients ≥ 1 year old, weighing 15 kg. This analysis aimed to evaluate dupilumab from LIBERTY TREET trial (NCT03633617), with prior history different interventions.
Abstract Background Limited literature is available on EoE disease duration and response to therapy. Dupilumab approved for in patients aged ≥12 years, weighing ≥40 kg, the EU, ≥1 year, ≥15 USA Canada. Aims To assess long-term efficacy of dupilumab with stratified by baseline duration. Methods In Part B LIBERTY TREET (NCT03633617), received 24 weeks 300 mg or placebo weekly (qw). Eligible who completed through 52 (Part C). Co-primary endpoints were proportion achieving peak esophageal...
Summary Background Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality life (QoL) EoE patients. Methods The multicountry cross-sectional survey, Adelphi Disease Specific Programme™, collected physician patient-reported HCRU, QOL with past/current proton pump inhibitor use ongoing dysphagia-related symptoms (September to December 2020)...
The QUEST (ClinicalTrials.gov identifier NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab, 200 or 300 mg, versus placebo every 2 weeks for 52 (QUEST) an additional 96 (TRAVERSE) in patients with uncontrolled, moderate-to-severe asthma. This analysis assessed dupilumab from who enrolled were stratified by a reduction fractional exhaled nitric oxide (Feno) level week QUEST. Patients Feno at least 25 ppb parent study baseline (PSBL) defined as those without...
Chronic Obstructive Pulmonary Disease (COPD) is a chronic, progressive disease that not curable. However, there are effective treatments available. In the UK, long-acting bronchodilators first-line for COPD patients requiring maintenance therapy, and several options The aim of this study to establish, from UK National Health Service (NHS) perspective, cost-effectiveness profile indacaterol, first once-daily beta2-agonist (LABA), compared with tiotropium salmeterol, in moderate severe COPD....
Severe, uncontrolled asthma and exacerbations in children are associated with abnormal lung function airway development, increased risk of chronic obstructive disease adulthood. The rationale for this post hoc analysis was to explore the relationship between changes exacerbation rates treated dupilumab.